154 related articles for article (PubMed ID: 29321965)
1. Prognostic score for life expectancy evaluation of lung cancer patients after bone metastasis.
Pruksakorn D; Phanphaisarn A; Settakorn J; Arpornchayanon U; Tantraworasin A; Chaiyawat P; Klangjorhor J; Teeyakasem P
J Bone Oncol; 2018 Mar; 10():1-5. PubMed ID: 29321965
[TBL] [Abstract][Full Text] [Related]
2. Estimating survival and clinical outcome in advanced non-small cell lung cancer with bone-only metastasis using molecular markers.
Meng C; Wei J; Tian J; Ma J; Liu N; Yuan Z; Zhao L; Wang P
J Bone Oncol; 2021 Dec; 31():100394. PubMed ID: 34703756
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis.
Tominaga H; Setoguchi T; Shimada H; Nagano S; Sasaki H; Ishidou Y; Sato M; Mizuno K; Inoue H; Komiya S
Mol Clin Oncol; 2017 Nov; 7(5):897-902. PubMed ID: 29181185
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
5. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
6. Prediction of skeletal-related events in patients with non-small cell lung cancer.
Aiba H; Kimura T; Yamagami T; Watanabe N; Sakurai H; Kimura H; Shimozaki S; Yamada S; Otsuka T
Support Care Cancer; 2016 Aug; 24(8):3361-7. PubMed ID: 26980332
[TBL] [Abstract][Full Text] [Related]
7. Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach.
Jacobson D; Cadieux B; Higano CS; Henry DH; Bachmann BA; Rehn M; Stopeck AT; Saad H
J Bone Oncol; 2022 Jun; 34():100423. PubMed ID: 35378840
[TBL] [Abstract][Full Text] [Related]
8. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
Xu S; Cao S; Yu Y
J Cancer Res Ther; 2021 Dec; 17(7):1636-1642. PubMed ID: 35381733
[TBL] [Abstract][Full Text] [Related]
9. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
10. Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity?
Deberne M; Ropert S; Billemont B; Daniel C; Chapron J; Goldwasser F
BMC Cancer; 2014 Jun; 14():416. PubMed ID: 24913188
[TBL] [Abstract][Full Text] [Related]
11. Novel risk scoring system for immune checkpoint inhibitors treatment in non-small cell lung cancer.
Li C; Shi M; Lin X; Zhang Y; Yu S; Zhou C; Yang N; Zhang J; Zhang F; Lv T; Liu H; Song Y
Transl Lung Cancer Res; 2021 Feb; 10(2):776-789. PubMed ID: 33718021
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors after complete resection of pN2 non-small cell lung cancer.
Sonobe M; Date H; Wada H; Okubo K; Hamakawa H; Teramukai S; Matsumura A; Nakagawa T; Sumitomo S; Miyamoto Y; Okumura N; Takeo S; Kawakami K; Aoki M; Kosaka S;
J Thorac Cardiovasc Surg; 2013 Oct; 146(4):788-95. PubMed ID: 23810113
[TBL] [Abstract][Full Text] [Related]
15. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study.
Bragstad S; Flatebø M; Natvig GK; Eide GE; Skeie GO; Behbahani M; Pedersen PH; Enger PØ; Skeie BS
J Neurosurg; 2018 Jul; 129(1):71-83. PubMed ID: 28820304
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study.
Gao X; Chen M; Liu X; Shi Y; Liang H; Zhou Q; Zhao J; Pan R; Zhong W; Xu Y; Wang M
Front Oncol; 2022; 12():879554. PubMed ID: 35558520
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in patients with spinal metastasis: a systematic review and meta-analysis.
Luksanapruksa P; Buchowski JM; Hotchkiss W; Tongsai S; Wilartratsami S; Chotivichit A
Spine J; 2017 May; 17(5):689-708. PubMed ID: 27988342
[TBL] [Abstract][Full Text] [Related]
18. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
[TBL] [Abstract][Full Text] [Related]
19. Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer.
Demirelli B; Babacan NA; Ercelep Ö; Öztürk MA; Kaya S; Tanrıkulu E; Khalil S; Hasanov R; Alan Ö; Telli TA; Koca S; Arıbal ME; Kuzan B; Dane F; Yumuk PF
Nutr Cancer; 2021; 73(2):230-238. PubMed ID: 32270713
[No Abstract] [Full Text] [Related]
20. Adrenalectomy does not improve survival rates of patients with solitary adrenal metastasis from non-small cell lung cancer.
Huang SH; Kong QL; Chen XX; He JY; Qin J; Chen ZG
Ther Clin Risk Manag; 2017; 13():355-360. PubMed ID: 28356749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
